The trajectory of Sildenafil presents a nuanced case for observers in the pharmaceutical sector. While initially a blockbuster success, generating huge profits, the intellectual property lapse and the subsequent flood of generic alternatives have drastically changed earnings. This raises questions about the long-term sustainability of similar thera